Skip to main content
Top

29-08-2016 | Comorbidities | Article

Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study

Journal: Clinical Rheumatology

Authors: Katelynn M. Wilton, Cynthia S. Crowson, Eric L. Matteson

Publisher: Springer London

Abstract

Malignancy is a major cause of death in patients with inflammatory disease. The risk of individual malignancies is altered in some inflammatory diseases, such as rheumatoid arthritis and psoriasis. This study aimed to examine malignancy incidence in patients with psoriatic arthritis (PsA), a related inflammatory disease. Institutional cancer registry and medical record linkage systems were retrospectively reviewed in a population-based incidence cohort of 217 patients with PsA and 434 age- and sex-matched comparators. Malignancy rates were compared using adjusted Cox models. Incidence of overall malignancy (excluding NMSC; hazard ratio (HR) 1.64; 95 % confidence interval (CI) 1.03–2.61) and breast cancer (HR 3.59; 95 % CI 1.22–10.61), but not NMSC (HR 1.23; 95 % CI 0.72–2.09), were significantly elevated in the PsA cohort. Age and female sex were similar predisposing risk factors in both cohorts. The overall incidence of malignancy, as well as the risk of breast cancer, was higher in patients with PsA than in the general population.
Literature
1.
Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740–1751. doi:10.​1002/​art.​20311 CrossRefPubMed
2.
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212. doi:10.​1186/​s13075-015-0728-9 CrossRefPubMedPubMedCentral
3.
Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126(10):2194–2201. doi:10.​1038/​sj.​jid.​5700410 CrossRefPubMed
4.
Frentz G, Olsen JH (1999) Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140(2):237–242CrossRefPubMed
5.
Gladman DD (2008) Mortality in psoriatic arthritis. Clin Exp Rheumatol 26(5 Suppl 51):S62–S65PubMed
6.
St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA (2011) Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol 173(9):1059–1068. doi:10.​1093/​aje/​kwq482 CrossRefPubMedPubMedCentral
7.
Ernste FC, Sanchez-Menendez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H (2015) Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 67(7):1015–1021. doi:10.​1002/​acr.​22536 CrossRef
8.
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 36(2):361–367. doi:10.​3899/​jrheum.​080691 CrossRefPubMedPubMedCentral
9.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. doi:10.​1002/​art.​21972 CrossRefPubMed
10.
Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706CrossRefPubMed
11.
Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD (2008) Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58(1):82–87. doi:10.​1002/​art.​23185 CrossRefPubMed
12.
Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66(5):1282–1290. doi:10.​1002/​art.​38339 CrossRefPubMed
13.
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64(6):1035–1050. doi:10.​1016/​j.​jaad.​2010.​09.​734 CrossRefPubMedPubMedCentral
14.
Fanto M, Peragallo MS, Pietrosanti M, Di Rosa R, Picchianti Diamanti A, Salemi S, D'Amelio R (2016) Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience. Intern Emerg Med 11(1):31–40. doi:10.​1007/​s11739-015-1270-0 CrossRefPubMed